NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
8 December 2023
RUA LIFE SCIENCES PLC
("RUA Life Sciences", the "Company" or the "Group")
Result of Retail Offer
Further to the announcement dated 30 November 2023, RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, the world leading long-term implantable biostable polyurethane, is pleased to announce that, following the closing of the Retail Offer on the BookBuild platform on 7 December 2023, 2,784,566 Ordinary Shares will be issued at the Issue Price of 11 pence per Retail Offer Share in connection with the Retail Offer, raising an additional £0.31 million.
Consequently, conditional on the passing of the Resolutions at the General Meeting (and, in relation to the Subscription Shares only, the announcement of Group's interim accounts ending the closed period), 36,363,636 Placing Shares, 727,272 Subscription Shares and 2,784,566 Retail Offer Shares, resulting in a total of 39,875,474 new Ordinary Shares, will be issued in relation to the Placing, Subscription and Retail Offer, raising total gross proceeds of £4.4 million.
Admission and Total Voting Rights
Application has been made for the Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on or around 19 December 2023.
The Retail Offer Shares will, when issued, be credited as fully paid up and will have the same rights as the Existing Ordinary Shares including, voting, dividend, return of capital and other rights, and will on issue be free of all claims, liens, charges, encumbrances and equities.
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 62,060,272 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 62,060,272. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the Placing and Retail Offer announcement dated 30 November 2023, unless otherwise defined in this announcement.
For further information contact:
| RUA Life Sciences Bill Brown, Chairman Caroline Stretton, Group Managing Director |
Tel: +44 (0)1294 317073 Tel: +44 (0)1294 317073
|
| Cavendish Capital Markets Limited (Nominated Adviser and Broker) Giles Balleny/Dan Hodkinson (Corporate Finance) Charlie Combe (ECM) Michael Johnson (Sales) | Tel: +44 (0)20 7220 0500
|
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
| RUA Contract Manufacture: | End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
|
| RUA Biomaterials: | Licensor of Elast-EonTM polymers to the medical device industry.
|
| RUA Vascular: | Commercialisation of open surgical vascular grafts and patches
|
| RUA Structural Heart:
| Development of polymeric leaflet systems for heart valves. |
This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
